UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Initial management of high-risk gestational trophoblastic neoplasia

Authors
Ross S Berkowitz, MD
Donald Peter Goldstein, MD
Neil S Horowitz, MD
Section Editors
Barbara Goff, MD
Don S Dizon, MD, FACP
Deputy Editors
Sadhna R Vora, MD
Sandy J Falk, MD, FACOG

INTRODUCTION

Gestational trophoblastic disease (GTD) defines a group of conditions that arise from an aberrant fertilization event. When GTD recurs or there is evidence of metastatic disease, it is called gestational trophoblastic neoplasia (GTN) and comprises four subtypes of disease:

Invasive mole

Choriocarcinoma

Placental site trophoblastic tumor (PSTT)

Epithelioid trophoblastic tumor (ETT)

                     

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Tue Jan 06 00:00:00 GMT+00:00 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Cole LA, Sasaki Y, Muller CY. Normal production of human chorionic gonadotropin in menopause. N Engl J Med 2007; 356:1184.
  2. Lurain JR, Elfstrand EP. Single-agent methotrexate chemotherapy for the treatment of nonmetastatic gestational trophoblastic tumors. Am J Obstet Gynecol 1995; 172:574.
  3. Schink JC, Singh DK, Rademaker AW, et al. Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease. Obstet Gynecol 1992; 80:817.
  4. Bolis G, Bonazzi C, Landoni F, et al. EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT). Gynecol Oncol 1988; 31:439.
  5. Bower M, Newlands ES, Holden L, et al. EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. J Clin Oncol 1997; 15:2636.
  6. Kim SJ, Bae SN, Kim JH, et al. Risk factors for the prediction of treatment failure in gestational trophoblastic tumors treated with EMA/CO regimen. Gynecol Oncol 1998; 71:247.
  7. Matsui H, Suzuka K, Iitsuka Y, et al. Combination chemotherapy with methotrexate, etoposide, and actinomycin D for high-risk gestational trophoblastic tumors. Gynecol Oncol 2000; 78:28.
  8. Escobar PF, Lurain JR, Singh DK, et al. Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy. Gynecol Oncol 2003; 91:552.
  9. Turan T, Karacay O, Tulunay G, et al. Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia. Int J Gynecol Cancer 2006; 16:1432.
  10. Cagayan MS. High-risk metastatic gestational trophoblastic neoplasia. Primary management with EMA-CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy. J Reprod Med 2012; 57:231.
  11. Lurain JR, Singh DK, Schink JC. Primary treatment of metastatic high-risk gestational trophoblastic neoplasia with EMA-CO chemotherapy. J Reprod Med 2006; 51:767.
  12. Deng L, Zhang J, Wu T, Lawrie TA. Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour. Cochrane Database Syst Rev 2013; :CD005196.
  13. Kim SJ, Bae SN, Kim JH, et al. Effects of multiagent chemotherapy and independent risk factors in the treatment of high-risk GTT--25 years experiences of KRI-TRD. Int J Gynaecol Obstet 1998; 60 Suppl 1:S85.
  14. Alifrangis C, Agarwal R, Short D, et al. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. J Clin Oncol 2013; 31:280.
  15. Newlands ES, Holden L, Seckl MJ, et al. Management of brain metastases in patients with high-risk gestational trophoblastic tumors. J Reprod Med 2002; 47:465.
  16. Newlands ES. The management of recurrent and drug-resistant gestational trophoblastic neoplasia (GTN). Best Pract Res Clin Obstet Gynaecol 2003; 17:905.
  17. Small W Jr, Lurain JR, Shetty RM, et al. Gestational trophoblastic disease metastatic to the brain. Radiology 1996; 200:277.
  18. Rustin GJ, Newlands ES, Begent RH, et al. Weekly alternating etoposide, methotrexate, and actinomycin/vincristine and cyclophosphamide chemotherapy for the treatment of CNS metastases of choriocarcinoma. J Clin Oncol 1989; 7:900.
  19. Bakri Y, Berkowitz RS, Goldstein DP, et al. Brain metastases of gestational trophoblastic tumor. J Reprod Med 1994; 39:179.
  20. Altintaş A, Vardar MA. Central nervous system involvement in gestational trophoblastic neoplasia. Eur J Gynaecol Oncol 2001; 22:154.
  21. Herrington S. Enhancing cure and palliation: radiation therapy in the treatment of metastatic gestational trophoblastic neoplasia. Semin Oncol 1995; 22:185.
  22. Yordan EL Jr, Schlaerth J, Gaddis O, Morrow CP. Radiation therapy in the management of gestational choriocarcinoma metastatic to the central nervous system. Obstet Gynecol 1987; 69:627.
  23. Athanassiou A, Begent RH, Newlands ES, et al. Central nervous system metastases of choriocarcinoma. 23 years' experience at Charing Cross Hospital. Cancer 1983; 52:1728.
  24. Lybol C, Thomas CM, Blanken EA, et al. Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia. Eur J Cancer 2013; 49:860.
  25. Even C, Pautier P, Duvillard P, et al. Actinomycin D, cisplatin, and etoposide regimen is associated with almost universal cure in patients with high-risk gestational trophoblastic neoplasia. Eur J Cancer 2014; 50:2082.
  26. Berkowitz RS, Goldstein DP. Current management of gestational trophoblastic diseases. Gynecol Oncol 2009; 112:654.
  27. Tomoda Y, Arii Y, Kaseki S, et al. Surgical indications for resection in pulmonary metastasis of choriocarcinoma. Cancer 1980; 46:2723.
  28. Fleming EL, Garrett L, Growdon WB, et al. The changing role of thoracotomy in gestational trophoblastic neoplasia at the New England Trophoblastic Disease Center. J Reprod Med 2008; 53:493.
  29. Jones WB, Romain K, Erlandson RA, et al. Thoracotomy in the management of gestational choriocarcinoma. A clinicopathologic study. Cancer 1993; 72:2175.
  30. Hoekstra AV, Lurain JR, Rademaker AW, Schink JC. Gestational trophoblastic neoplasia: treatment outcomes. Obstet Gynecol 2008; 112:251.
  31. Alazzam M, Hancock BW, Tidy J. Role of hysterectomy in managing persistent gestational trophoblastic disease. J Reprod Med 2008; 53:519.
  32. Doumplis D, Al-Khatib K, Sieunarine K, et al. A review of the management by hysterectomy of 25 cases of gestational trophoblastic tumours from March 1993 to January 2006. BJOG 2007; 114:1168.
  33. Lurain JR, Singh DK, Schink JC. Role of surgery in the management of high-risk gestational trophoblastic neoplasia. J Reprod Med 2006; 51:773.
  34. Pisal N, North C, Tidy J, Hancock B. Role of hysterectomy in management of gestational trophoblastic disease. Gynecol Oncol 2002; 87:190.
  35. Xu LT, Sun CF, Wang YE, Song HZ. Resection of pulmonary metastatic choriocarcinoma in 43 drug-resistant patients. Ann Thorac Surg 1985; 39:257.
  36. Wang YA, Song HZ, Xia ZF, Sun CF. Drug resistant pulmonary choriocarcinoma metastasis treated by lobectomy: report of 29 cases. Chin Med J (Engl) 1980; 93:758.
  37. Cagayan MS, Magallanes MS. The role of adjuvant surgery in the management of gestational trophoblastic neoplasia. J Reprod Med 2008; 53:513.
  38. Soper JT. Role of surgery and radiation therapy in the management of gestational trophoblastic disease. Best Pract Res Clin Obstet Gynaecol 2003; 17:943.
  39. Clark RM, Nevadunsky NS, Ghosh S, et al. The evolving role of hysterectomy in gestational trophoblastic neoplasia at the New England Trophoblastic Disease Center. J Reprod Med 2010; 55:194.
  40. Newlands ES, Mulholland PJ, Holden L, et al. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. J Clin Oncol 2000; 18:854.
  41. Newlands ES, Bower M, Fisher RA, Paradinas FJ. Management of placental site trophoblastic tumors. J Reprod Med 1998; 43:53.
  42. Papadopoulos AJ, Foskett M, Seckl MJ, et al. Twenty-five years' clinical experience with placental site trophoblastic tumors. J Reprod Med 2002; 47:460.
  43. Hyman DM, Bakios L, Gualtiere G, et al. Placental site trophoblastic tumor: analysis of presentation, treatment, and outcome. Gynecol Oncol 2013; 129:58.
  44. Kingdon SJ, Coleman RE, Ellis L, Hancock BW. Deaths from gestational trophoblastic neoplasia: any lessons to be learned? J Reprod Med 2012; 57:293.
  45. van Trommel NE, Massuger LF, Schijf CP, et al. Early identification of resistance to first-line single-agent methotrexate in patients with persistent trophoblastic disease. J Clin Oncol 2006; 24:52.
  46. You B, Pollet-Villard M, Fronton L, et al. Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias. Ann Oncol 2010; 21:1643.
  47. Kerkmeijer LG, Thomas CM, Harvey R, et al. External validation of serum hCG cutoff levels for prediction of resistance to single-agent chemotherapy in patients with persistent trophoblastic disease. Br J Cancer 2009; 100:979.
  48. Golfier F, Labrousse C, Frappart L, et al. [Evaluation of treatment relating to gestational trophoblastic tumor registered to the French Trophoblastic Disease Reference Center (TDRC) in Lyon from 1999 to 2005]. Gynecol Obstet Fertil 2007; 35:205.
  49. McNeish IA, Strickland S, Holden L, et al. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J Clin Oncol 2002; 20:1838.
  50. Lurain JR. Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia. Am J Obstet Gynecol 2011; 204:11.
  51. Lurain JR, Schink JC. Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia. J Reprod Med 2012; 57:219.
  52. Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet 2010; 376:717.
  53. Ahamed E, Short D, North B, et al. Survival of women with gestational trophoblastic neoplasia and liver metastases: is it improving? J Reprod Med 2012; 57:262.
  54. Committee on Practice Bulletins-Gynecology, American College of Obstetricians and Gynecologists. ACOG Practice Bulletin #53. Diagnosis and treatment of gestational trophoblastic disease. Obstet Gynecol 2004; 103:1365.
  55. Society of Gynecologic Oncologists Clinical Practice Guidelines. Practice guidelines: gestational trophoblastic disease. Oncology (Williston Park) 1998; 12:455.
  56. Lim AK, Agarwal R, Seckl MJ, et al. Embolization of bleeding residual uterine vascular malformations in patients with treated gestational trophoblastic tumors. Radiology 2002; 222:640.
  57. Yang JJ, Xiang Y, Wan XR, Yang XY. Diagnosis and management of uterine arteriovenous fistulas with massive vaginal bleeding. Int J Gynaecol Obstet 2005; 89:114.
  58. McGrath S, Harding V, Lim AK, et al. Embolization of uterine arteriovenous malformations in patients with gestational trophoblastic tumors: a review of patients at Charing Cross Hospital, 2000-2009. J Reprod Med 2012; 57:319.
  59. Goldstein DP, Zanten-Przybysz IV, Bernstein MR, Berkowitz RS. Revised FIGO staging system for gestational trophoblastic tumors. Recommendations regarding therapy. J Reprod Med 1998; 43:37.